Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 70-77

  Zhang, Yi ^a   Wang, Zhi ^a   Yu, Jin ^a   Shi, Jia zhong ^a   Wang, Chun ^a   Fu, Wei hua ^a   Chen, Zhi wen ^a   Yang, Jin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Cancer stem like cell; Cisplatin resistance; Epithelial mesenchymal transition

Indexed keywords

BMI1 PROTEIN; CELL MARKER; CISPLATIN; TRANSCRIPTION FACTOR NANOG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CANCER TISSUE; CELL RENEWAL; CELL STRAIN; CELL STRAIN T24; CELL SUBPOPULATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84862824245     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.010     Document Type: Article

References (38)

1. van Rhijn B.W., Burger M., Lotan Y., Solsona E., Stief C.G., Sylvester R.J., Witjes J.A., Zlotta A.R. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 2009, 56:430-442.
2. Bellmunt J., Albiol S., Suarez C., Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit. Rev. Oncol. Hematol. 2009, 69:211-222.
3. Zamble D.B., Lippard S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 1995, 20:435-439.
4. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu. Rev. Med. 2007, 58:267-284.
5. Clarke M.F., Fuller M. Stem cells and cancer: two faces of eve. Cell 2006, 124:1111-1115.
6. O'Brien C.S., Farnie G., Howell S.J., Clarke R.B. Are stem-like cells responsible for resistance to therapy in breast cancer. Breast Dis. 2008, 29:83-89.
7. + cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 2009, 106:16281-16286.
8. Fujii H., Honoki K., Tsujiuchi T., Kido A., Yoshitani K., Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int. J. Oncol. 2009, 34:1381-1386.
9. Dean M. Cancer stem cells: implications for cancer causation and therapy resistance. Discov. Med. 2005, 5:278-282.
10. Morrison R., Schleicher S.M., Sun Y., Niermann K.J., Kim S., Spratt D.E., Chung C.H., Lu B. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J. Oncol. 2011, 2011:941876.
11. Ning Z.F., Huang Y.J., Lin T.X., Zhou Y.X., Jiang C., Xu K.W., Huang H., Yin X.B., Huang J. Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J. Int. Med. Res. 2009, 37:621-630.
12. Oates J.E., Grey B.R., Addla S.K., Samuel J.D., Hart C.A., Ramani V.A., Brown M.D., Clarke N.W. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev. 2009, 18:1515-1522.
13. Yang Y.M., Chang J.W. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 2008, 26:725-733.
14. Bentivegna A., Conconi D., Panzeri E., Sala E., Bovo G., Vigano P., Brunelli S., Bossi M., Tredici G., Strada G., Dalpra L. Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci. 2010, 101:416-424.
15. Chan K.S., Espinosa I., Chao M., Wong D., Ailles L., Diehn M., Gill H., Presti J., Chang H.Y., van de Rijn M., Shortliffe L., Weissman I.L. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2009, 106:14016-14021.
16. He X., Marchionni L., Hansel D.E., Yu W., Sood A., Yang J., Parmigiani G., Matsui W., Berman D.M. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 2009, 27:1487-1495.
17. Wang J., Guo L.P., Chen L.Z., Zeng Y.X., Lu S.H. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007, 67:3716-3724.
18. Jia X., Li X., Xu Y., Zhang S., Mou W., Liu Y., Lv D., Liu C.H., Tan X., Xiang R., Li N. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J. Mol. Cell Biol. 2011, 3:230-238.
19. Jiang L., Li J., Song L. Bmi-1, stem cells and cancer. Acta. Biochim. Biophys. Sin. (Shanghai) 2009, 41:527-534.
20. Chiou S.H., Wang M.L., Chou Y.T., Chen C.J., Hong C.F., Hsieh W.J., Chang H.T., Chen Y.S., Lin T.W., Hsu H.S., Wu C.W. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010, 70:10433-10444.
21. Wu C., Alman B.A. Side population cells in human cancers. Cancer Lett. 2008, 268:1-9.
22. Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J., Aigner L., Brawanski A., Bogdahn U., Beier C.P. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67:4010-4015.
23. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
24. Neimark A.I., Klyzhina E.A., Neimark B.A., Mel'nik M.A. Effects of transcranial magnetotherapy on electroencephalographic parameters in females with overactive urinary bladder. Urologiia 2007, 40-44.
25. Chetty R., Serra S., Salahshor S. Nuclear expression of E-cadherin. Am. J. Surg. Pathol. 2008, 32:1269-1270.
26. Boyer L.A., Lee T.I., Cole M.F., Johnstone S.E., Levine S.S., Zucker J.P., Guenther M.G., Kumar R.M., Murray H.L., Jenner R.G., Gifford D.K., Melton D.A., Jaenisch R., Young R.A. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122:947-956.
27. Boiani M., Scholer H.R. Regulatory networks in embryo-derived pluripotent stem cells. Nat. Rev. Mol. Cell Biol. 2005, 6:872-884.
28. Cavaleri F., Scholer H.R. Nanog: a new recruit to the embryonic stem cell orchestra. Cell 2003, 113:551-552.
29. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., Morrison S.J., Clarke M.F. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
30. Molofsky A.V., He S., Bydon M., Morrison S.J., Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 2005, 19:1432-1437.
31. Liu S., Dontu G., Mantle I.D., Patel S., Ahn N.S., Jackson K.W., Suri P., Wicha M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66:6063-6071.
32. Ezeh U.I., Turek P.J., Reijo R.A., Clark A.T. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005, 104:2255-2265.
33. Wen J., Park J.Y., Park K.H., Chung H.W., Bang S., Park S.W., Song S.Y. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 2010, 39:622-626.
34. Pan Y., Jiao J., Zhou C., Cheng Q., Hu Y., Chen H. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology 2010, 77:283-288.
35. Bruggeman S.W., Hulsman D., Tanger E., Buckle T., Blom M., Zevenhoven J., van Tellingen O., van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12:328-341.
36. Schuringa J.J., Vellenga E. Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells. Curr. Opin. Hematol. 2010, 17:294-299.
37. Chang C.C., Shieh G.S., Wu P., Lin C.C., Shiau A.L., Wu C.L. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res. 2008, 68:6281-6291.
38. Atlasi Y., Mowla S.J., Ziaee S.A., Bahrami A.R. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int. J. Cancer 2007, 120:1598-1602.